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IgA1-containing immune complexes in IgA nephropathy dif-
ferentially affect proliferation of mesangial cells.
Background. Sera of patients with IgA nephropathy (IgAN)
contain circulating immune complexes (CIC) composed of
galactose-deficient IgA1 complexed with antiglycan antibod-
ies. The role of these CIC in the pathogenesis of IgAN is not
known.
Methods. We studied how proliferation of cultured mesan-
gial cells (MC) is affected by CIC prepared from sera of IgAN
patients and healthy control subjects using size-exclusion chro-
matography. CIC-containing fractions were added to serum-
starved MC in culture, and cell proliferation was measured
using 3H-thymidine incorporation. The results were confirmed
by staining MC using an antibody against proliferating cell nu-
clear antigen.
Results. The incubation of starved MC with serum fractions
with Mr 800 to 900 kD, rich with galactose-deficient IgA1, stimu-
lated proliferation, while fractions with smaller complexes were
inhibitory. Furthermore, CIC-containing larger molecular mass
fractions isolated from serum of an IgAN patient collected
during an episode of macroscopic hematuria stimulated MC
proliferation more than CIC obtained during a subsequent qui-
escent phase. To examine the role of IgA, we removed IgA1
from serum before fractionation. The resultant IgA1-depleted
fractions were devoid of stimulatory IgA-CIC. Sera of IgAN
patients were also fractionated after addition of desialylated
galactose-deficient polymeric IgA1 to form additional immune
complexes. Supplementation with a small quantity of this IgA1
increased cellular proliferation in assays using serum fractions
of Mr ≥800 to 900 kD; uncomplexed IgA1 did not affect MC
proliferation significantly. In contrast, supplementation with a
larger quantity of this IgA1 inhibited cellular proliferation in
assays using serum fractions of Mr 700 to 800 kD.
Dr. Matousovic’s current address is the Department of Internal
Medicine, School of Medicine 2, Charles University, Prague, Czech
Republic.
Key words: glomerulonephritis, glycosylation, O-linked glycans, im-
munoglobulin A (IgA), autoimmunity.
Received for publication October 10, 2003
and in revised form May 19, 2004, and July 29, 2004
Accepted for publication August 18, 2004
C© 2005 by the International Society of Nephrology
Conclusion. Overall, these findings suggest that CIC contain-
ing aberrantly glycosylated IgA1 affect proliferation of MC in
vitro and, thus, likely play a role in the pathogenesis of IgAN.
IgA nephropathy (IgAN), the most common type
of glomerulonephritis worldwide, is characterized by
mesangial deposits of IgA1, often with codeposits of C3,
and IgG or IgM, or both [1–5]. Proliferation of mesan-
gial cells (MC) and expansion of extracellular matrix are
found in patients with mild clinical disease, but progres-
sive glomerular and interstitial sclerosis leads to end-
stage renal disease in 30% to 40% of patients within
20 years after diagnosis [1]. IgAN recurs in approximately
50% to 60% of renal allografts [6–8]; in contrast, immune
deposits in a kidney transplanted inadvertently from a
donor with subclinical IgAN to a patient with non-IgAN
renal disease clear within several weeks [9], suggesting
that the cause of IgAN is extrarenal.
Serum or plasma of IgAN patients often exhibits
increased levels of IgA-containing circulating immune
complexes (CIC) [10–12]. Several lines of evidence sug-
gest that the mesangial immune deposits likely originate
from CIC: (1) IgA1, but not IgA2, is present in CIC of
most IgAN patients [10, 13] and in the mesangial deposits
[3]; (2) shared idiotypic determinants are expressed on
CIC and in mesangial deposits [14] (however, without a
disease-specific idiotype [15]); (3) IgAN-CIC [16–19] are
characterized by galactose (Gal)-deficient hinge-region
O-linked glycans of IgA1 [12, 20], and the same Gal de-
ficiency was also detected in IgA1 in the mesangium [21,
22]; and (4) Gal-deficient IgA1 and IgA-IgG CIC are
also found in sera of Henoch-Scho¨nlein purpura (HSP)
patients, but only in those with renal involvement [23, 24].
Recent reports from several laboratories support the
proposal that O-linked glycans in the hinge region
of some IgA1 molecules in the circulation of IgAN
patients are deficiently galactosylated [12, 16–20, 23,
25–36]. In the absence of Gal, the terminal sugar is
504
Novak et al: Stimulation of mesangial cells by IgA1 complexes from IgAN patients 505
N-acetylgalactosamine (GalNAc) [12, 20]. Subsequently,
these sugar moieties or hinge-region glycopeptides [37,
38] are recognized by naturally occurring antibodies
with antiglycan or antihinge region peptide specificities
[20, 38], and CIC are formed [36]. The circulating Gal-
deficient IgA1 is exclusively in CIC and is mostly a
J-chain-containing polymer (p) [20]. Our earlier study
showed that the IgAN-CIC containing Gal-deficient
IgA1 bound to MC more efficiently than uncomplexed
IgA, and that a greater amount of CIC from an IgAN
patient bound to MC than CIC from a healthy control
patient [39]. To study activation of MC in vitro, CIC
(700–1000 kD) were isolated from sera of IgAN patients
and healthy volunteers by size-exclusion chromatogra-
phy, fractions were added to serum-starved MC in cul-
ture, and cellular proliferation was measured using 3H-
thymidine incorporation. Our results support the hypoth-
esis that aberrantly glycosylated IgA1-containing CIC are
involved in the pathogenesis of IgAN.
METHODS
Patients and control subjects
Serum samples were obtained from 12 biopsy-proven
IgAN patients (mean age 36.8 years, 9 males, 3 females;
serum creatinine ranged from 0.7 to 5.1 mg/dL, dipstick
urinary protein from 0 to 4+, and blood from 0 to 4+) and
5 healthy control subjects (mean age 38.2 years, 3 males,
2 females; normal serum creatinine levels and urine neg-
ative by dipstick for protein and blood). Seven IgAN
patients had serum samples collected during an acute
episode of macroscopic hematuria, and one of them had
an additional sample collected several weeks after res-
olution of the macroscopic hematuria. The study was
approved by the Institutional Review Board; informed
written consent was obtained before collecting samples.
Cell cultures and proliferation assays
Human MC (2 different preparations of primary cells)
were purchased from BioWhittaker (Walkersville, MD,
USA). Cells from passages 3 to 4 were maintained in
RPMI 1640 supplemented with 20% fetal calf serum
(FCS), L-glutamine (2 mmol/L), penicillin G (100 U/mL),
streptomycin (0.1 mg/mL) in humidified 5% CO2 atmo-
sphere at 37◦C [39]. Purity of MC was assessed by cell
morphology (stellar shape) and immunohistochemical
features, including positive staining for vimentin, con-
firmed by Western blot and negative staining for factor
VIII–related antigen and cytokeratin (to exclude contam-
ination with endothelial and epithelial cells, respectively).
Proliferation experiments were conducted in 24-well
tissue culture plates seeded with MC. At 85% to 95% con-
fluence, MC were serum-starved (in a medium contain-
ing 0.5% FCS) [39] for 24 hours before the experiment.
Serum fractions were pooled (each two-total 0.4 mL; see
below), filter-sterilized, mixed with an equal volume of
the medium containing 1% FCS (to obtain final concen-
tration 0.5% FCS), and incubated in duplicates (0.4 mL
in each well) with MC in humidified 5% CO2 atmo-
sphere at 37◦C for 20 hours. The culture medium alone
and medium supplemented with platelet-derived growth
factor (PDGF; R&D Systems, Minneapolis, MN, USA)
(10 ng/mL) were used as negative and positive controls,
respectively. For the last 4 hours of incubation, 100 lL 3H-
thymidine (1 lCi; PerkinElmer, Wellesley, MA, USA) in
the culture medium was added to each well. MC in each
well were washed two times with PBS to remove free
3H-thymidine [each wash was filtered using MultiScreen-
HA filter plates (Millipore, Bedford, MA, USA) to cap-
ture detached cells]. Washed cells were lysed with 0.2 mL
0.3 mol/L NaOH, then each well was washed with 0.1 mL
5% acetic acid, and all washes and the filter were com-
bined and added to 5 mL scintillation liquid in a scintilla-
tion vial. The radioactivity was determined using a Wallac
liquid scintillation counter 1409DSA (PerkinElmer). Av-
erage values were calculated from duplicates for each
serum fraction and expressed either directly as counts per
minute (cpm) or relatively to the negative control (cpm
of sample/cpm of the control) as relative proliferation.
Thus, ratios greater than 1.0 indicate stimulation, while
ratios below 1.0 indicate inhibition.
Isolation of serum fractions enriched with CIC
Serum fractions enriched with CIC were isolated by
precipitation of serum from 3 IgAN patients and 3 nor-
mal healthy control subjects with 7% polyethylene gly-
col (PEG) [40] and from 9 IgAN patients and 4 normal
healthy control subjects by size-exclusion chromatogra-
phy. For the latter procedure, serum (0.5 mL) was fil-
tered using 0.45 lm filter (Pall Corporation, Ann Arbor,
MI, USA) and fractionated on a calibrated Superose 6
column (600 × 12 mm; Amersham Biosciences Corpora-
tion, Piscataway, NJ, USA) in phosphate-buffered saline
(PBS) [20, 39]. Fractions containing proteins of appar-
ent molecular mass over 700 kD were collected, and
the aliquots were analyzed for IgA, IgG, HAA-binding
IgA1, and IgA-IgG complexes using enzyme-linked im-
munosorbent assay (ELISA). The profiles of IgA, IgG,
and HAA were essentially identical with that shown in
Figure 5 of our previous publication [20]. The remainder
of each two fractions was pooled (total 0.4 mL), filter-
sterilized, and added to MC as described above.
Depletion and supplementation of serum IgA
Serum (0.6 mL) was incubated overnight at 4◦C with
immobilized jacalin (EY Laboratories, San Mateo, CA,
USA) or anti-IgA1 monoclonal antibody (H69-7.1) [20]
to remove IgA1 or with immobilized Protein G (Sigma
Chemical Co., St. Louis, MO, USA) to remove IgG. Then,
the serum sample was filtered using 0.45 lm filter (Pall
Corporation) and fractionated as described above.
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To supplement serum with Gal-deficient IgA1, 20 lg
or 50 lg of IgA1 proteins (a naturally Gal-deficient
myeloma pIgA1 (Mce) or a jacalin-affinity and size-
exclusion chromatography-purified pIgA1 from an IgAN
patient) were added to the serum samples from an IgAN
patient to form additional immune complexes in vitro.
After overnight incubation at 4◦C, the serum sample was
filtered using 0.45 lm filter (Pall Corporation) and pro-
cessed as described above.
ELISA
Serum fractions were analyzed by ELISA for IgA, IgG,
HAA-binding IgA1, IgA-IgG complexes, and IgG sub-
classes bound to IgA [20, 39]. Biotin-labeled HAA was
purchased from Sigma, goat biotin-labeled antihuman
IgG- and IgA-specific antibodies were purchased from
Southern Biotechnology Associates, Inc. (Birmingham,
AL, USA), and an F(ab’)2 fragment of anti-IgA (heavy
chain-specific) was purchased from ICN Biomedicals, Inc.
(Irvine, CA, USA). IgG subclass-specific antibodies used
in our assays have been previously described [20].
Immunohistochemical staining
MC were grown on Lab-Tech chambered slides (Nalge/
Nunc, Hoperville, IL, USA), serum-starved as described
above, and incubated with control medium or stimu-
lated with CIC-containing serum fractions or PDGF
for 24 hours. MC were then washed, fixed in 3%
paraformaldehyde, and stained with antibody directed
against proliferating cell nuclear antigen (PCNA; Dako,
Carpinteria, CA, USA) to detect proliferating cells or
stained with the DeadEnd colorimetric TUNEL (TdT-
mediated dUTP Nick-End Labeling) system (Promega,
Madison, WI, USA) to detect apoptotic cells. For PCNA
staining, antigen heat-retrieval was used [41].
Sections of renal biopsies from two patients with IgAN
(different patients than those who provided serum sam-
ples; diffuse mesangial proliferation without crescents),
two patients with diffuse lupus nephritis (WHO class
IV), three patients with non-IgA proliferative glomeru-
lonephropathy (one minimal, one moderate, one dif-
fuse), and one patient with minimal change disease were
processed for PCNA and TUNEL staining as described
above.
Statistical analysis
Comparison between group means was performed us-
ing Student t test. P values equal to or less than 0.05 were
considered statistically significant.
RESULTS
Proliferation of MC in the presence of sera from IgAN
patients and control subjects
Native sera from IgAN patients and healthy control
subjects stimulated proliferation of serum-starved MC,
Table 1. Proliferation of human mesangial cells stimulated with 5%
native human serum from four IgAN patients and four healthy
control subjects, Gal-deficient pIgA1 protein (Mce; 10 lg), and PDGF
(10 ng/mL)
Sample Thymidine incorporationb cpm
Negative controla 9490
PDGF 29,711
Gal-deficient pIgA1 8564
IgAN sera 78,625 ± 30,578
Normal healthy control sera 68,457 ± 6940
aRPMI 1640 medium with 0.5% FCS, L-glutamine (2 mmol/L), penicillin G
(100 U/mL), streptomycin (0.1 mg/mL).
bAverage or average ± SD.
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Fig. 1. Proliferation of human MC stimulated with 5% human serum
from IgAN patients (serum samples were randomly selected from pa-
tients with serum creatinine range 1.1 to 4.5 mg/dL, no apparent hema-
turia, and proteinuria 0 to 3+) correlated with the amount of Gal-
deficient IgA (r = 0.832, P < 0.05). Number of samples did not allow
any analyses of possible correlation between clinical status and prolifer-
ation. Proliferation of MC was assessed using 3H-thymidine incorpora-
tion after 20 hours; Gal-deficiency of IgA was analyzed by determining
the binding of HAA lectin using ELISA. Each value represents mean
from duplicate assay.
as determined by 3H-thymidine incorporation (Table 1).
Sera from IgAN patients showed somewhat higher stim-
ulation than sera from control subjects, but the difference
was not statistically significant. Because the formation of
sublytic complement complexes (C5-9) can activate MC
[42–44], we also tested MC proliferation in the presence
of heat-inactivated sera. Under these conditions, MC pro-
liferation was by 15% to 28% greater when compared to
the stimulation with native (e.g., untreated) sera (results
not shown), possibly due to aggregation of immunoglob-
ulins. MC responded to a positive control, PDGF, by at
least a 2- to 3-fold increase in 3H-thymidine incorpora-
tion. In contrast, Gal-deficient pIgA1 only slightly re-
duced 3H-thymidine incorporation.
Stimulation with sera from IgAN patients increased
proliferation proportionally to the levels of Gal-deficient
IgA1 (measured as HAA binding) in the samples
(Fig. 1). This may be related to our observation that
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Fig. 2. Proliferation of MC after stimulation with fractions from native
serum collected from an IgAN patient during an episode of macroscopic
hematuria (closed circles) and then later at a quiescent stage (open cir-
cles). Serum samples (0.5 mL) were fractionated on a calibrated column
of Superose 6; 0.25-mL fractions were collected, every two consecutive
fractions were pooled and filter-sterilized before adding in duplicates to
the culture of serum-starved MC in 24-well plates. After 20 hours incu-
bation, 3H-thymidine was added and the culture incubated for another
4 hours. MC were then washed and lyzed, and 3H-thymidine incorpo-
ration was measured using a liquid scintillation counter. Each value
represents an average from a duplicate. CIC of 800 to 900 kD collected
at the time of macroscopic hematuria stimulated MC proliferation more
than CIC of similar size collected after macroscopic hematuria had re-
solved. Furthermore, MC proliferation-stimulating CIC of >900 kD
were detected only at the time of macroscopic hematuria.
Gal-deficient IgA1 bound to MC with higher affinity than
normally glycosylated IgA1 [39]. Because Gal-deficient
IgA1 is present in CIC [12, 20], we isolated immune
complexes from three IgAN patients and three control
subjects using precipitation with 7% PEG and exam-
ined their effects on MC proliferation. 3H-thymidine
incorporation after stimulation with 1 to 2 lg protein
was about 2-fold greater for samples from IgAN pa-
tients than from healthy control subjects. However, be-
cause of inconsistency of results in further experiments,
and because PEG precipitates serum proteins other than
just immune complexes [40], we tested MC responses
to serum fractions from IgAN patients and control sub-
jects enriched with IgA-containing CIC prepared by size-
exclusion chromatography.
Gal-deficient IgA1-containing CIC fractionated from
serum of an IgAN patient collected during an episode
of macroscopic hematuria stimulated MC proliferation
more than CIC obtained during a subsequent quiescent
phase
A serum sample from an IgAN patient was collected
at the time of macroscopic hematuria and several weeks
after resolution; both samples were fractionated on a cal-
ibrated column of Superose 6 and tested as previously
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Fig. 3. Relative proliferation of human MC stimulated with fractions
of sera from four healthy control subjects (open symbols; A) and four
IgAN patients without macroscopic hematuria (closed symbols; B).
Serum samples (0.5 mL) were fractionated on a calibrated column of
Superose 6, and fractions processed and analyzed as described in Fig. 2.
Each value represents an average from a duplicate.
described. CIC of 800 to 900 kD from the first sample
stimulated MC proliferation more than CIC from the
second sample (Fig. 2). Furthermore, MC proliferation-
stimulating CIC of >900 kD were detected in only the
first sample. These results indicated that there may be
changes in the CICs associated with clinical activity of
the disease.
Stimulation of MC proliferation by CIC-containing
fractions from sera of IgAN patients and healthy control
subjects
To determine proliferative response of MC incubated
in the presence of serum fractions from IgAN patients
and healthy control subjects, we subjected sera from four
IgAN patients without macroscopic hematuria and four
healthy control subjects to size-exclusion chromatogra-
phy on a calibrated Superose 6 column. In each exper-
iment, we compared one IgAN patient’s sample with
one control sample. Fractions from two IgAN patients
and from one control containing Gal-deficient IgA1-
CIC with molecular mass 800 to 900 kD stimulated MC
proliferation (Fig. 3). To compare more samples in one
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Fig. 4. Proliferation of human mesangial cells after stimulation with
fractions from sera from four IgAN patients with macroscopic hema-
turia. Serum samples (0.5 mL) were fractionated on a calibrated column
of Superose 6 and fractions analyzed as described in Fig. 2. All four sam-
ples appeared to have similar pattern of CIC: inhibitory CIC of about
700 to 800 kD and stimulatory CIC of about 800 to 900 kD.
experiment, we pooled Superose 6 fractions containing
CIC of 800 to 900 kD from sera of three IgAN patients
without macroscopic hematuria and from three healthy
control subjects. The results showed that the samples
from IgAN patients induced, on average, 37% higher
3H-thymidine incorporation in MC compared to the sam-
ples from healthy control subjects.
When MC proliferative responses were determined in
the presence of CIC-containing fractions from sera of
four IgAN patients with active macroscopic hematuria,
two types of IgA-containing CIC, one stimulatory and
the other inhibitory, were detected (Fig. 4). Notably, all
four samples exhibited proliferation activity of 800 to
900 kD fractions and inhibitory activity of ∼700 to 800 kD
fractions. The fractions with proliferation-stimulating ac-
tivity in all samples (800–900 kD) corresponded to CIC
containing most of the Gal-deficient IgA1 (detected as
HAA-reactive IgA by ELISA) [20].
Results obtained using 3H-thymidine incorporation
were confirmed with immunohistochemical staining of
the cells with anti-PCNA antibody. Staining of serum-
starved MC (cultured in RPMI 1640 + 0.5% FCS) showed
about 50% cells weakly expressing PCNA; stimulation
with Gal-deficient IgA1-containing CIC (800–900 kD)
increased the number of MC expressing PCNA (93%
were PCNA-positive with moderate to strong intensity).
As a positive control, PDGF-stimulated MC showed that
more than 98% of them stained intensely for PCNA. We
also examined cell apoptosis using TUNEL staining, but
did not find any changes with MC incubated with vari-
ous fractions, including the CIC inhibiting MC prolifera-
tion. Thus, the inhibition of 3H-thymidine incorporation
by 700 to 800 kD CIC appeared to be a true inhibition of
proliferation rather than acceleration of apoptosis.
Interestingly, we observed similar patterns of PCNA
staining (increased numbers of PCNA-positive MC;
Fig. 5) and TUNEL staining (few positive cells) in the
mesangia of the renal biopsies from two IgAN patients.
This observation suggests that MC both in vitro and in
the glomerular mesangia of IgAN patients respond to
IgAN-CIC by enhanced proliferation with no apparent
induction of apoptosis.
Role of IgG and IgA in MC-stimulating/inhibiting
activity
The MC-stimulating as well as MC-inhibiting CIC con-
tained IgA and IgG, as determined by ELISA and pre-
viously published information [12, 20, 39], but there was
no direct evidence implicating these components in the
stimulation of MC proliferation. The stimulatory frac-
tions contained IgG bound to IgA1 predominantly of
the IgG3 subclass, followed in descending order by IgG1,
IgG2, and traces of IgG4. The inhibitory fractions con-
tained relatively more IgG bound to IgA1, predominantly
of the IgG3 and IgG1 subclasses.
To examine a possible stimulatory effect of this IgA,
we fractionated an aliquot of serum from an IgAN pa-
tient before and after adsorption on jacalin-agarose to
remove IgA1 before fractionation. Removal of IgA1 ex-
tinguished the MC-stimulating and dampened the inhibit-
ing activities (Fig. 6A). Furthermore, we eluted the bound
IgA-CIC from jacalin with melibiose and observed stim-
ulatory activity associated with CIC of apparent molec-
ular mass about 800 to 900 kD after fractionation using
size-exclusion column (Fig. 6A). Removal of IgA1 us-
ing immobilized monoclonal antibody specific for IgA1
had an effect similar to that of jacalin—removal of MC-
stimulating activity.
To determine the role of IgG in the interactions of
CIC with MC, we examined the proliferation of MC in
the presence of serum from which the free and com-
plexed IgG were removed by affinity chromatography
on agarose-conjugated protein G. Adsorption on protein
G removed part of the inhibitory activity from an IgAN
serum (Fig. 6B). In contrast, protein-G adsorption re-
moved most of the inhibitory, as well as part of the stim-
ulatory, activities from the serum of a healthy control
subject (Fig. 6C).
These data suggested that MC activation by CIC
was dependent on the composition and size of these
complexes. Most Gal-deficient IgA1 was present in the
fractions stimulating MC proliferation, while inhibitory
fractions were rich in IgG. The finding that protein G re-
moved very little of the stimulatory activity and only a
portion of the inhibitory activity from IgAN sera, while
jacalin or anti-IgA antibody removed both stimulatory
and inhibitory activities, may reflect differential three-
dimensional organization of IgG and IgA in these CIC
and, thus, differential availability for various Ig receptors.
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BA
Fig. 5. Representative pictures of PCNA staining of glomeruli from renal biopsies of patients with a minimal change disease (A) and IgAN (B).
PCNA-positive nuclei in both figures are marked by arrows.
Gal-deficient IgA1 added to serum increases
MC-stimulating activity
To extend the data from studies with IgA1-depleted
sera, Gal-deficient IgA1 was added to serum from an
IgAN patient. In addition to CIC, this serum con-
tained an excess of IgG and IgA1 antibodies with
specificity for Gal-deficient O-linked hinge region gly-
cans; therefore, additional complexes were formed be-
fore the fractionation. Two types of desialylated IgA1
were used: a naturally Gal-deficient myeloma pIgA1
(Mce) and a jacalin-affinity-purified and size-exclusion
chromatography-purified pIgA1 from an IgAN patient.
In both instances, we added 20 lg of each IgA prepara-
tion to 0.5 mL serum. After incubation, the serum samples
were fractionated and the activities of fractions tested as
before. Supplementation of IgAN serum with pIgA1 iso-
lated from the same patient increased MC proliferation,
mostly with 800 to 900 kD CIC (Fig. 7A). Addition of
20 lg myeloma IgA1 (Mce) increased MC proliferation
activity that was associated with fractions containing 800
to 900 kD CIC, as well as with fractions containing 900
to 1000 kD CIC (Fig. 7B). ELISA revealed that these
fractions contained newly formed IgG-IgA complexes
(Fig. 7C). No increase in proliferation was detected when
10 lg IgA1 myeloma protein was used instead of CIC
(Table 1).
In contrast, supplementation of serum with a larger
amount of IgA1 (50 lg) resulted in the increase of in-
hibitory activity of the serum fractions containing low-
molecular-weight immune complexes (Fig. 7B). This
result suggested that the antigen/antibody ratio plays an
important role in the biological properties of the resultant
immune complexes.
DISCUSSION
IgA-containing immune deposits in the renal
mesangium associated with mesangial proliferative
activity and matrix expansion are the hallmark of IgAN.
We have examined with in vitro experiments the binding
and proliferative responses of MC to IgA1-containing
CIC and uncomplexed IgA1. It is known that in patients
with IgAN the circulating IgA1 with aberrant hinge
region glycans is bound to IgG or IgA1 with antiglycan
specificity [20]. Our earlier studies have shown that vari-
ous forms of uncomplexed myeloma IgA1 (monomeric,
polymeric, with intact or enzymatically modified hinge
region glycans) bound to human MC in vitro with
relatively low affinity and did not alter significantly their
proliferation. IgA1-CIC prepared by PEG precipitation
or by size-exclusion chromatography bound to MC
with considerably higher affinity and, in some instances,
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Fig. 6. Proliferation of human MC after stimulation with fractions
from native serum (open symbols) from an IgAN patient and the same
serum after adsorption on immobilized jacalin lectin to remove IgA1
(closed symbols; A). The jacalin-eluted sample was also fractionated
and the fractions were added to MC (filled triangles, A). One aliquot
of serum (0.5 mL) from an IgAN patient with macroscopic hematuria
was directly fractionated on a calibrated column of Superose 6 while
the other aliquot was first adsorbed on jacalin-agarose to remove IgA1
and then fractionated. MC were grown and the fractions analyzed as
described in Fig. 2. Both stimulatory CIC and inhibitory CIC (although
this native serum sample did not exhibit as large an inhibitory effect as
other samples) were removed by jacalin adsorption. The jacalin-eluted
sample was also fractionated and the fractions retained their ability
to stimulate MC proliferation (triangles, A). Proliferation of human
mesangial cells after stimulation with fractions from native serum (open
symbols) of an IgAN patient and the same serum after adsorption on
immobilized Protein G (closed symbols; B). Protein G adsorption,
stimulated proliferation. When assayed by 3H-thymidine
incorporation, proliferation of MC incubated with IgA1-
CIC from IgAN patients and healthy control subjects did
significantly differ, consistent with a previous report [45].
However, further experiments demonstrated two types
of IgA-CIC: stimulating and inhibiting MC proliferation
in vitro. Thus, experiments using whole serum or total
CIC cannot be clearly interpreted without separating
IgA-CIC according to their molecular masses.
To our knowledge, this is the first report of two types of
functionally distinct IgA1-containing CIC that differen-
tially affect quiescent MC. While it is not clear whether
both types of CIC play a role in vivo, the quality (e.g., size
and composition) may determine the biological activity
of these complexes. For example, smaller CIC may be
efficiently catabolized in the liver while larger CIC may
escape hepatic catabolism and instead penetrate into the
renal mesangium.
We undertook additional studies to define whether
proteins other than IgG and IgA1 (such as acute phase
proteins) are present in the active fractions. First, using
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) and proteomics, we have identified a2
macroglobulin and its precursor, fibronectin, and hap-
toglobin 2 precursor (J. Novak et al, unpublished results).
These proteins were in all three types of fractions (e.g.,
stimulatory, inhibitory, and having no effect on MC pro-
liferation), indicating that they were not likely to alter
MC proliferation and may be in complexes or aggregates
of various molecular masses. The same proteins remained
in the nonbinding fractions after removing IgA1 by affin-
ity chromatography, and the resultant IgA1-depleted
fractions did not alter MC proliferation. Furthermore,
the IgA1-containing preparations of CIC eluted from
the affinity (anti-IgA1) column and analyzed by SDS-
PAGE did not contain detectable levels of proteins other
than immunoglobulins. Thus, based on these prelimi-
nary results, both stimulatory and inhibitory activities
of serum fractions with IgA1-containing CIC may be
attributed mostly to different properties of these com-
plexes rather than to the presence of proteins other than
immunoglobulins.
The importance of Gal-deficient IgA1 in the stimula-
tion of MC proliferation is obvious: depletion of IgA1-
CIC abolished the proliferation-stimulating activity. On
the other hand, uncomplexed Gal-deficient IgA1 did not
increase MC proliferation, suggesting that to stimulate
by removing free and complexed IgG, diminished the inhibitory effect.
Proliferation of human mesangial cells after stimulation with fractions
from native serum (open symbols) of a healthy control and the same
serum after adsorption on immobilized Protein G (closed symbols; C).
Protein G adsorption removed most of the inhibitory CIC and some of
the stimulatory CIC.
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Fig. 7. Proliferation of MC after stimulation with fractions from native
IgAN serum (open symbols) and IgAN serum supplemented with 20
lg polymeric desialylated IgA1 from the same IgAN patient (closed
symbols) (A). Proliferation of MC after stimulation with fractions from
IgAN serum supplemented with 20 lg (closed circles) or 50 lg (open
triangles) desialylated polymeric Gal-deficient IgA1 myeloma protein
(Mce) to form additional immune complexes in vitro (B). IgA-IgG com-
plexes in individual fractions of native serum (open symbols) and IgAN
serum supplemented with 20 lg desialylated polymeric Gal-deficient
IgA1 myeloma protein (closed symbols) was determined by ELISA
(C). Newly formed IgG-IgA complexes were detected in the fractions
stimulating MC proliferation.
MC proliferation it must be bound in immune complexes.
Indeed, supplementation of serum with Gal-deficient
IgA1 formed more CIC and thereby increased stimula-
tory activity. These observations suggest a requirement
for additional factor(s) (e.g., potential ligands other than
IgA1, such as IgG) that allows activation of MC by
CIC but not by uncomplexed IgA1. This model implies
cross-linking of different receptors. An alternative model
assumes that only in CIC does the IgA1 conformation
permit cross-linking of a single type of receptor. How-
ever, in either case, both the quality and quantity of IgA1-
contaning CIC apparently determine the effect on MC in
vitro. These conclusions were further supported by the
observation that while supplementation of serum with
a smaller amount (20 lg) of desialylated Gal-deficient
pIgA1 increased the stimulatory activity of serum frac-
tions containing CIC with high-molecular mass, supple-
mentation with a larger amount (50 lg) increased the in-
hibitory activity of serum fractions containing CIC with
low-molecular mass (Fig. 7).
While our data suggested a role of IgA1 in IgA-
containing CIC from IgAN patients for binding to MC
[39] and consequential stimulation of MC proliferation
(this paper), the nature of the mesangial receptor(s) re-
mains unresolved [46]. A current consensus proposes that
this receptor(s) differs from the Fca receptor (CD89), the
asialoglycoprotein receptor (ASGPR), and the polymeric
Ig receptor [47–50]. Two other receptors have emerged
as possible candidates: CD71 (transferrin receptor) [51,
52] and Fca/l receptor [53, 54]. We have confirmed ex-
pression of CD71 mRNA in proliferating MC in culture
(unpublished data and [55]). CD71 binds only IgA1 [51],
while MC bind both IgA subclasses [39, 50], suggesting
existence of another IgA receptor. Theoretically, it may
be the Fca/l receptor [54]. In contrast, pIgA1 from IgAN
patients induced MC to secrete macrophage migration
inhibitory factor and TNF-a, likely through an unidenti-
fied IgA receptor different from CD89, ASGPR, CD71,
or Fca/l [56]. While the nature of the IgA1-CIC recep-
tor on MC is unknown, we speculate, based on the fact
that IgA1-containing CIC but not free IgA1 stimulated
MC proliferation, that a coordinated binding and cross-
linking of two IgA (or other) receptors may be required
to trigger cellular proliferation. Further studies are neces-
sary to clarify the expression and pathogenic importance
of these candidate receptors and their potential splicing
variants.
CONCLUSION
IgA-containing CIC with the highest content of Gal-
deficient IgA1 stimulated proliferation of MC in vitro.
While it is not clear why CIC of different sizes differ-
entially altered MC proliferation, we propose that fac-
tors such as molecular form and quantity of Gal-deficient
IgA1, number and localization of GalNAc epitopes in the
hinge region, isotype and affinity of the antiglycan anti-
bodies, and handling and disposal of the formed CIC are
among the important factors that affect quality and quan-
tity of CIC and their pathogenic potential. Understanding
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the mechanisms by which these pathogenic CIC form and
activate MC [57–59] may provide a rational basis for the
design of future interventional strategies.
ABBREVIATIONS
Nonstandard abbreviations: CIC, circulating immune
complexes; GalNAc, N-acetylgalactosamine; HAA, He-
lix aspersa lectin; HSP, Henoch-Scho¨nlein purpura; IgAN,
IgA nephropathy; MC, mesangial cells; PCNA, prolif-
erating cell nuclear antigen; PEG, polyethylene glycol;
TUNEL, TdT-mediated dUTP nick-end labeling.
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